Abstract:Background: Post-acute sequelae of COVID-19 (PASC), also now known as long COVID, has become a major global health and economic burden. Previously, we provided evidence that there is a significant insoluble fibrin amyloid microclot load in the circulation of individuals with long COVID, and that these microclots entrap a substantial number of inflammatory molecules, including those that might prevent clot breakdown. Scientifically, the most challenging aspect of this debilitating condition is that traditional pathology tests such as a serum CRP (C-reactive protein) may not show any significant abnormal inflammatory markers, albeit these tests measure only the soluble inflammatory molecules. Elevated, or abnormal soluble biomarkers such as IL-6, D-Dimer or fibrinogen indicate an increased risk for thrombosis or a host immune response in COVID-19. The absence of biomarkers in standard pathology tests, result in a significant amount of confusion for patients and clinicians, as patients are extremely sick or even bed-ridden but with no regular identifiable reason for their disease. Biomarkers that are currently available cannot detect the molecules present in the microclots we identified and are therefore unable to confirm their presence or the mechanisms that drive their formation. Methods: Here we analysed the protein content of double-digested microclots of 99 long COVID patients and 29 healthy controls. The patients suffering from long COVID reported their symptoms through a questionnaire completed by themselves or their attending physician. Results: Our long COVID cohort's symptoms were found to be in line with global findings, where the most prevalent symptoms were constant fatigue (74%,) cognitive impairment (71%) and depression and anxiety (30%). Our most noteworthy findings were a reduced level of plasma Kallikrein compared to our controls, an increased level of platelet factor 4 (PF4) von Willebrand factor (VWF), and a marginally increased level of α-2 antiplasmin (α-2-AP). We also found a significant presence of antibodies entrapped inside these microclots. Conclusion: Our results confirm the presence of pro-inflammatory molecules that may also contribute to a failed fibrinolysis phenomenon, which could possibly explain why individuals with long COVID suffer from chronic fatigue, dyspnoea, or cognitive impairment. In addition, significant platelet hyperactivation was noted. Hyperactivation will result in the granular content of platelets being shed into the circulation, including PF4. Overall, our results provide further evidence of both a failed fibrinolytic system in long COVID/PASC and the entrapment of many proteins whose presence might otherwise go unrecorded. These findings might have significant implications for individuals with pre-existing comorbidities, including cardiovascular disease and type 2 diabetes.

Challenging the current hypothesis that thrombosis is responsible for the post-COVID-19 condition

The Risk of Thrombosis after Acute-Covid-19 Infection

Pathophysiological mechanisms of thrombosis in acute and long COVID-19

Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system

Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin

Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium

Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC)

The Long Term Residual Effects of COVID-Associated Coagulopathy

Coagulopathy and Thrombosis as a Result of Severe COVID-19 Infection: A Microvascular Focus

A review of pathophysiological mechanism, diagnosis, and treatment of thrombosis risk associated with COVID-19 infection

The COVID-19 thrombus: distinguishing pathological, mechanistic, and phenotypic features and management

Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation

Abstract WP326: Microclots, Erythrocytes, and the Coagulation Cascade in Long COVID

A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications

BIOMARKERS OF ENDOTHELIAL DYSFUNCTION AND CLOTTING DYSREGULATION POST COVID-19- A SUBSTUDY OF CARTESIAN

Increased Levels of Inflammatory and Endothelial Biomarkers in Blood of Long COVID Patients Point to Thrombotic Endothelialitis

Analysis of Coagulation Profile and Possible Mechanism of Coagulation Activation in COVID-19 Patients: A Systematic Literature Review

Persistent endotheliopathy in the pathogenesis of long COVID syndrome

Gut-brain pathogenesis of post-acute COVID-19 neurocognitive symptoms

Is there a rationale for hyperbaric oxygen therapy in the patients with Post COVID syndrome?

Dysregulated platelet function in patients with postacute sequelae of COVID-19